Autopsy report · NCT05707676
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LB4330 in Patients With Advanced Solid Tumors（MEETCD8-001）
Cause of deathFunding or business
“Due to adjustments in the sponsor's development strategy, it has been decided to terminate the study.”
Life of this trial
- Ran for about 2 years 1 month before it stopped.
- 40 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- L & L Bio Co., Ltd., Ningbo, China
- Sponsor type
- Industry
- Conditions
- Solid Tumor
- Interventions
- LB4330
- Participants
- 40
- Sites
- 1
- Countries
- China
Trials that died the same way
- A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
“Voluntarily terminate the study since the sponsor's development strategy was adjusted.” - A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors
“The study was terminated due to the sponsor's research and development strategy adjustment.” - Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients
“Based on the adjustment of the sponsor's R\&D strategy, it is decided to terminate this study in advance.” - Study of RP-6306 With FOLFIRI in Advanced Solid Tumors
“Sponsor decided to terminate the study” - Study of Viziatek ISL™ Refractive Phakic Intra Sulcus Lens for Refraction Adjustment in Blind Volunteers
“Sponsor decision to terminate the study”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.